ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Facebook Comments